China (Mainland)
Diamondsupplier 
factory supply DMF Lubiprostone CAS NO.136790-76-6
- Min.Order: 1 Kilogram
- Payment Terms: L/C,T/T,Other
- Product Details
Keywords
- Lubiprostone
- Rubiprostone
- 136790-76-6
Quick Details
- ProName: factory supply DMF Lubiprostone
- CasNo: 136790-76-6
- Molecular Formula: C23H34N5O14P
- Appearance: White crystallization
- Application: anti- Virus response
- DeliveryTime: in two weeks
- PackAge: 1kg/tin
- Port: SHANGHAI BEIJING
- ProductionCapacity: 1 Metric Ton/Day
- Purity: USP/EP/BP
- Transportation: AIR SEA TRAIN
- LimitNum: 1 Kilogram
Superiority
We are very compeitive on Lubiprostone.Our mfr is with DMF document.
| Product Name: | Lubiprostone |
| Synonyms: | Lubiprostone API;7-[(1r,4r,6r,9r)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo[4.3.0]non-9-yl]heptanoic acid;lubiprostone;Rubiprostone;SPI 0211;UNII-7662KG2R6K;AMITIZA LUBIPROSTONE;(11a)-16,16-Difluoro-11-hydroxy-9,15-dioxo-prostan-1-oic Acid;Ru 0211;(11α)-16,16-Difluoro-11-hydroxy-9,15-dioxo-prostan-1-oic Acid |
| CAS: | 136790-76-6 |
| MF: | C20H32F2O5 |
| MW: | 390.47 |
| EINECS: | 634-172-9 |
| Product Categories: | Inhibitors;Prostaglandin;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Other APIs |
| Mol File: | 136790-76-6.mol |
Details
| General Description | Lubiprostone (brand name: Amitiza) is a drug that is prescribed as a treatment for acute idiopathic constipation that is associated with bloating, stomach pain and straining in bowel movements. The drug is prescribed in cases where a patient is experiencing infrequent bowel movements that may persist for about 3 months or a longer period of time without necessarily being resultant of certain medications or diseases. The drug may also be used to relieve constipation that may result from specific opioid (narcotic) use amongst people who have persistent pain that is not caused by cancer. Lubiprostone is classified as a laxative and its mechanism of action entails enhancing the flow of fluid into the bowel for easier bowel movements. |
| Pharmacology | Marketed under the trade name Amitiza, Lubiprostone is a chloride channel activator which is mainly used for the treatment of idiopathic (due to an unknown cause) chronic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. Lubiprostone is an oral medication approved by the FDA in January 2006. The mechanism of action of lubiprostone is the same as chloride channel activator. It functions by binding and activating ClC-2 chloride channels in the apical membrane of the gastrointestinal epithelium, which produces an efflux of chloride-rich fluid secretion. The increased amounts of secretions are effective to soften the stool, increase motility, promote spontaneous bowel movements (SBM), and speed up transit of stool in the colon. Therefore, the relevant symptoms, such as abdominal pain and bloating, can be reduced. |
